By Shepard Ambellas
ZMapp soon to be approved for commercial human use
SAN DIEGO, Calif. (INTELLIHUB) — A Toronto based bio-defense firm named Defyrus announced July 15, 2014, that they would be entering in an exclusive revenue sharing deal with Leaf Biopharmaceutical, a San Diego based company, for an experimental new Ebola vaccine which at the time was not tested on humans.
Under the license Leaf Biopharmaceutical is responsible for the ongoing development of ZMapp, worldwide. Once designed and fast-tracked for human use under Department of Defense authority, ZMapp will then likely be distributed worldwide for the current Ebola outbreak which is likely to span the globe as announced by the Center for Disease Control earlier Friday.
The New York Times reported:
At least two of the countries affected by the Ebola outbreak, Liberia and Nigeria, have asked for the drug, according to a spokesman for the Centers for Disease Control and Prevention.
A perception in the region of unfairness in distributing the medicine could undermine the already shaky willingness of some Africans to trust the Western relief efforts. Dr. Armand Sprecher, a public health specialist for the aid group Doctors Without Borders, said it was unfortunate that the first doses went to white Americans “because it confirms all the suspicions people have.” But, he said, he did not foresee that perception as undermining the relief effort, adding that if effective drugs were available, it could bolster the effort’s credibility and give people an incentive to seek medical care.
“At the moment, our big problem is finding the patients in a timely way and convincing them to come to the treatment center,” he said. “If you don’t have a carrot to hang out there and bring people in, then you can’t contain it.”
About the author:
Shepard Ambellas is the founder and editor-in-chief of Intellihub News and the maker of SHADE the Motion Picture. You can also find him on Twitter and Facebook. Shepard also appears on the Travel Channel series America Declassified.